Blog
RSS FeedPosted by Michael Wonder on 29 Sep 2022
Europe's generic drugmakers say they may cut output due to energy bills
28 September 2022 - Europe's drugmakers have warned they may stop making some cheap generic medicines because of surging electricity ...
Posted by Michael Wonder on 18 Feb 2022
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
18 February 2022 - Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions. ...
Posted by Michael Wonder on 28 Oct 2021
Repurposing of authorised medicines: pilot to support not for profit organisations and academia
28 October 2021 - EMA and the Heads of Medicines Agencies are launching a pilot project to support the repurposing ...
Posted by Michael Wonder on 28 Feb 2019
“Repurposing” off-patent drugs offers big hopes of new treatments
28 February 2019 - Towards the end of 2014 a 66-year-old British man named Alistair had a seizure. A scan ...
Posted by Michael Wonder on 07 Oct 2017
Mylan, in partnership with Synthon, receives marketing authorisation approval in Europe for first generic for Copaxone 40 mg/mL
5 October 2017 - Mylan has exclusive rights for glatiramer acetate in several key European markets. ...
Posted by Michael Wonder on 18 Jul 2017
EU regulators charge Teva over pay-for-delay drug deal
17 July 2017 - EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon ...
Posted by Michael Wonder on 05 Sep 2016
EMA publishes EPAR for Aerivio Spiromax
5 September 2016 - The EMA has published an EPAR for Teva Pharmaceuticals' version of GSK's Seretide/Advair. ...